Multiple myeloma combo trial pulled before it even started
NCT ID NCT04392648
First seen Jan 11, 2026 · Last updated May 01, 2026 · Updated 19 times
Summary
This study was designed to test the safety and best dose of a new drug called TAK-573 when given with other cancer medicines to people whose multiple myeloma had returned or stopped responding to treatment. The trial was withdrawn before any participants were enrolled, so no results are available. It aimed to find a dose that could be used in future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.